RetinaLyze System
RetinaLyze System A/S is a Denmark-based software company specializing in artificial intelligence (AI) and telemedicine solutions for the optometry and healthcare industries. Their core product, RetinaLyze®, is a screening software that utilizes AI to analyze fundus images and OCT-scans for signs of eye diseases like diabetic retinopathy, age-related macular degeneration, and glaucoma. It functions as a clinical decision support system (CDSS) or a screening tool, offering instant results and reducing manual workload by up to 60%. The software is designed to be safe, fast, efficient, secure, and easy-to-use, enabling lower-trained staff to perform screenings. RetinaLyze has been used in hospitals, eye clinics, and optical chains since 2013, having performed over 6 million screenings. Their business model appears to be SaaS, with offerings including a web app and an API for integration into other healthcare systems. The company aims to make eye testing more affordable and accessible, preventing vision loss through early detection.
RetinaLyze System
RetinaLyze System A/S is a Denmark-based software company specializing in artificial intelligence (AI) and telemedicine solutions for the optometry and healthcare industries. Their core product, RetinaLyze®, is a screening software that utilizes AI to analyze fundus images and OCT-scans for signs of eye diseases like diabetic retinopathy, age-related macular degeneration, and glaucoma. It functions as a clinical decision support system (CDSS) or a screening tool, offering instant results and reducing manual workload by up to 60%. The software is designed to be safe, fast, efficient, secure, and easy-to-use, enabling lower-trained staff to perform screenings. RetinaLyze has been used in hospitals, eye clinics, and optical chains since 2013, having performed over 6 million screenings. Their business model appears to be SaaS, with offerings including a web app and an API for integration into other healthcare systems. The company aims to make eye testing more affordable and accessible, preventing vision loss through early detection.
TL;DR
Product: RetinaLyze® — AI-driven screening software for fundus images and OCT scans
Founded: December 2013
Regulatory / Quality: CE-marked and ISO 13485:2016 certified
Usage: Used in hospitals, eye clinics and optical chains; reported >6 million screenings
Business model: SaaS with web app and API integration
Company Overview
Problem Domain
Automated retinal disease screening and telemedicine for optometry and healthcare providers.
Founded
2013
Industry
Medical software / Healthtech
Tech Stack
Funding Track Record
One disclosed funding round listed as Seed on Jan 1, 2014; amount and investor details not specified in provided evidence.